Clinical trial

A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017

NCT04927858

Study summary

ClinicalTrials.gov

A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Empagliflozin Normalized identity: empagliflozin View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2018-04-02

PhaseN/A

Conditions

Type 2 Diabetes Mellitusverified · MONDO: type 2 diabetes mellitus

Interventions

EmpagliflozinDRUG · verified · RxNorm: empagliflozin

Sponsors & collaborators

Boehringer Ingelheimlead sponsor

Mapped research locations

StockholmSweden1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04927858 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.